NASDAQ:TCDATricida Stock Price, Forecast & News

Tricida's stock was trading at $28.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TCDA stock has decreased by 3.1% and is now trading at $27.17. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tricida.

Tricida is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tricida.

Tricida Inc (NASDAQ:TCDA) announced its quarterly earnings results on Thursday, May, 7th. The company reported ($1.49) earnings per share for the quarter, missing analysts' consensus estimates of ($1.41) by $0.08. View Tricida's earnings history.

3 brokers have issued twelve-month price objectives for Tricida's shares. Their forecasts range from $48.00 to $50.00. On average, they expect Tricida's share price to reach $49.33 in the next year. This suggests a possible upside of 81.6% from the stock's current price. View analysts' price targets for Tricida.

Press coverage about TCDA stock has been trending very negative recently, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tricida earned a news sentiment score of -3.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutTricida.

Some companies that are related to Tricida include United Therapeutics (UTHR), Myokardia (MYOK), Reata Pharmaceuticals (RETA), Forty Seven (FTSV), Mirati Therapeutics (MRTX), Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), BridgeBio Pharma (BBIO), PPD (SDGR), Global Blood Therapeutics (GBT), GW Pharmaceuticals PLC- (GWPH), Nektar Therapeutics (NKTR), Zai Lab (ZLAB), Evotec (EVTCY) and ChemoCentryx (CCXI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Gilead Sciences (GILD), Madrigal Pharmaceuticals (MDGL), Myovant Sciences (MYOV), Arena Pharmaceuticals (ARNA), Atara Biotherapeutics (ATRA), Biohaven Pharmaceutical (BHVN), Crispr Therapeutics (CRSP), CytomX Therapeutics (CTMX), Exelixis (EXEL) and Amicus Therapeutics (FOLD).

(TCDA) raised $175 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Tricida's stock is owned by a number of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (7.51%), BlackRock Inc. (5.48%), Redmile Group LLC (4.26%), JPMorgan Chase & Co. (3.01%), Cormorant Asset Management LP (1.76%) and Vivo Capital LLC (1.05%). Company insiders that own Tricida stock include Beek Jeroen B Van, Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP, Steffen Pietzke and Wilhelm Stahl. View institutional ownership trends for Tricida.

TCDA stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Driehaus Capital Management LLC, Cormorant Asset Management LP, Deutsche Bank AG, State Street Corp, International Biotechnology Trust PLC, Morgan Stanley, and Redmile Group LLC. Company insiders that have sold Tricida company stock in the last year include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Gerrit Klaerner, Klaus R Dr Veitinger, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP, and Wilhelm Stahl. View insider buying and selling activity for Tricida.

TCDA stock was acquired by a variety of institutional investors in the last quarter, including Vivo Capital LLC, BlackRock Inc., Ikarian Capital LLC, New York State Common Retirement Fund, Burrage Capital Management LLC, Two Sigma Investments LP, Nuveen Asset Management LLC, and Alyeska Investment Group L.P.. Company insiders that have bought Tricida stock in the last two years include Beek Jeroen B Van, Edward J Hejlek, Geoffrey M Parker, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Sandra I Coufal, and Steffen Pietzke. View insider buying and selling activity for Tricida.

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TCDA stock can currently be purchased for approximately $27.17.

Tricida has a market capitalization of $1.36 billion. The company earns $-176,810,000.00 in net income (profit) each year or ($3.72) on an earnings per share basis. Tricida employs 76 workers across the globe.

The official website for Tricida is www.tricida.com.

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]